Kenneth Shain, MD, PhD, associate member in the Malignant Hematology Program and director of the Myeloma Research Center at Moffitt Cancer Center and assistant professor at the Morsani College of Medicine at the University of South Florida, discusses the rationale for adding chimeric antigen receptor (CAR) T-cell therapy in earlier lines of therapy for relapsed/refractory […]